Intelligent Bio Solutions Inc. to Showcase Groundbreaking Pharmacokinetic Study at ADLM 2025 Clinical Lab Expo

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is poised to share its significant pharmacokinetic (PK) study findings at the upcoming ADLM 2025 Clinical Lab Expo in Chicago. The study focuses on the company's Intelligent Fingerprinting Drug Screening System, showcasing its ability to accurately detect codeine levels in fingerprint sweat, matching the precision of blood and saliva tests. This innovation represents a leap forward in drug screening technology, providing a swift, non-invasive, and respectful method for individuals undergoing testing in various sectors.

Daniel Brown, Head of Clinical Affairs at INBS, is scheduled to present the study's outcomes during the Poster Hall sessions. The Intelligent Fingerprinting Drug Screening System stands out for its efficiency, delivering results in less than ten minutes with a sample collection process that takes only seconds. This feature makes it especially valuable for industries where safety is paramount. The system's adoption across 24 countries, with over 450 accounts in sectors like construction, manufacturing, and drug treatment organizations, underscores its global impact and versatility.

The presentation at the ADLM 2025 Clinical Lab Expo is a testament to INBS's commitment to advancing drug screening technologies. The study not only confirms the system's reliability but also hints at its potential applications beyond drug screening, paving the way for future innovations in medical testing. For further information on the study and INBS's pioneering solutions, visit https://ibn.fm/suGlJ.